# Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome

> **NCT01629212** · PHASE4 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.**

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Tiropramide HCl 100mg
- **DRUG:** Octylonium bromide 20mg

## Key facts

- **NCT ID:** NCT01629212
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** — (—)
- **Last updated:** 2012-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01629212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01629212, "Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01629212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*